Humacyte posts trauma trial results, registers new Phase 2a coronary CTEV study for CABG
Humacyte's Phase 2/3 ATEV vascular trauma trial reports completed results, while a new Phase 2a study of its coronary vessel for bypass grafting has been registered.
Two Humacyte registry updates this week span a completed trauma study with newly posted results and a freshly listed coronary trial that has not yet begun enrolling.
- Humacyte's Phase 2/3 trial of the Acellular Tissue Engineered Vessel (ATEV) in patients with vascular trauma is now marked completed, with the primary outcome measuring the primary patency rate of the Human Acellular Vessel at Day 30 across the full study population that received the device.1 The study enrolled 72 participants1 and results were first posted on 2026-07-29.
- Humacyte registered a new Phase 2a study, NCT07730528, testing its Coronary Tissue Engineered Vessel (CTEV) as a bypass conduit in patients undergoing coronary artery bypass grafting. The study is designed to evaluate safety and efficacy of the CTEV as a vascular conduit for CABG in patients with coronary artery disease2 and is not yet recruiting, with an estimated enrollment of 10 participants2 and estimated start in 2026-09.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.